Status:
COMPLETED
Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies
Lead Sponsor:
Gruppo Italiano Trapianto di Midollo Osseo
Conditions:
Myeloid Malignancies
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The experimental treatment consists in the application of a therapeutic strategy with post Transplant High-Dose Cyclophosphamide as GvHD Prophylaxis in Patients Receiving 1-Antigen/Allele HLA Mismatch...
Detailed Description
The experimental treatment consists in the application of a therapeutic strategy with post Transplant High-Dose Cyclophosphamide as GvHD Prophylaxis in Patients Receiving 1-Antigen/Allele HLA Mismatch...
Eligibility Criteria
Inclusion
- Acute myeloid leukemia in complete remission Myelodysplastic syndrome Indication for allo-HCT No available HLA identical sibling donor or HLA matched unrelated donor Activation of an alternative donor search Presence of a 1 antigen/allele mismatched (7/8 HLA matched) unrelated donor ECOG performance status \<2 Written and signed informed consent
Exclusion
- left ventricular ejection fraction \< 40% FEV1, FVC, DLCO \<50% of predicted LFT \> 5 times the upper limit of normal creatinine clearance \< 40 ml/min Previous allogeneic Hemopoietic Stem Cell Transplantation
Key Trial Info
Start Date :
January 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 20 2022
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT03270748
Start Date
January 15 2020
End Date
November 20 2022
Last Update
March 10 2023
Active Locations (33)
Enter a location and click search to find clinical trials sorted by distance.
1
Azienda Ospedaliera SS Antonio e Biagio
Alessandria, Italy
2
Ospedali Riuniti
Ancona, Italy
3
Ospedale Moscati
Avellino, Italy
4
Policlinico di Bari-Ematologia con trapianti
Bari, Italy